Karen Mittu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karen Mittu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Angela B. Mariotto
National Cancer Institute 1 Division of Cancer Control and Population Sciences Bethesda, Maryland
27 shared publications - Jennifer L. Stevens
Information Management Services, Inc , Calverton, MD
27 shared publications - Nadia Howlader
Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute Bethesda Maryland USA
27 shared publications - Ron A. Dewar
Cancer Care Program, Nova Scotia Health Authority, Nova Scotia, Canada
27 shared publications - Theresa P. Devasia
National Cancer Institute 1 Division of Cancer Control and Population Sciences Bethesda, Maryland
27 shared publications - K. Robin Yabroff
Surveillance, Prevention & Health Services Research, American Cancer Society , Atlanta, GA
1 shared publication
Latest Publications
Cost‐of‐care discussions for individuals with advanced non–small cell lung cancer and melanoma: Findings from a large, population‐based pilot study
Background: Costs of cancer care can result in patient financial hardship; many professional organizations recommend provider discussions about treatment costs as part of high-quality care. In this pilot study, the authors examined patient-provider cost discussions documented in the medical records of individuals who were diagnosed with advanced non-small cell lung cancer (NSCLC) and melanoma-cancers with recently approved, high-cost treatment options. Methods: Individuals who were newly diagnosed in 2017-2018 with stage III/IV NSCLC (n = 1767) and in 2018 with stage III/IV melanoma (n = 689) from 12 Surveillance, Epidemiology, and End Results regions were randomly selected for the National Cancer Institute Patterns of Care Study. Documentation of cost discussions was abstracted from the medical record. The authors examined patient, treatment, and hospital factors associated with cost discussions in multivariable logistic regression analyses. Results: Cost discussions were documented in the medical records of 20.3% of patients with NSCLC and in 24.0% of those with melanoma. In adjusted analyses, privately insured (vs. publicly insured) patients were less likely to have documented cost discussions (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.37-0.80). Patients who did not receive systemic therapy or did not receive any cancer-directed treatment were less likely to have documented cost discussions than those who did receive systemic therapy (OR, 0.39 [95% CI, 0.19-0.81] and 0.46 [95% CI, 0.30-0.70], respectively), as were patients who were treated at hospitals without residency programs (OR, 0.64; 95% CI, 0.42-0.98). Conclusions: Cost discussions were infrequently documented in the medical records of patients who were diagnosed with advanced NSCLC and melanoma, which may hinder identifying patient needs and tracking outcomes of associated referrals. Efforts to increase cost-of-care discussions and relevant referrals, as well as their documentation, are warranted.
Cost‐of‐care discussions for individuals with advanced non–small cell lung cancer and melanoma: Findings from a large, population‐based pilot study
Background: Costs of cancer care can result in patient financial hardship; many professional organizations recommend provider discussions about treatment costs as part of high-quality care. In this pilot study, the authors examined patient-provider cost discussions documented in the medical records of individuals who were diagnosed with advanced non-small cell lung cancer (NSCLC) and melanoma-cancers with recently approved, high-cost treatment options. Methods: Individuals who were newly diagnosed in 2017-2018 with stage III/IV NSCLC (n = 1767) and in 2018 with stage III/IV melanoma (n = 689) from 12 Surveillance, Epidemiology, and End Results regions were randomly selected for the National Cancer Institute Patterns of Care Study. Documentation of cost discussions was abstracted from the medical record. The authors examined patient, treatment, and hospital factors associated with cost discussions in multivariable logistic regression analyses. Results: Cost discussions were documented in the medical records of 20.3% of patients with NSCLC and in 24.0% of those with melanoma. In adjusted analyses, privately insured (vs. publicly insured) patients were less likely to have documented cost discussions (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.37-0.80). Patients who did not receive systemic therapy or did not receive any cancer-directed treatment were less likely to have documented cost discussions than those who did receive systemic therapy (OR, 0.39 [95% CI, 0.19-0.81] and 0.46 [95% CI, 0.30-0.70], respectively), as were patients who were treated at hospitals without residency programs (OR, 0.64; 95% CI, 0.42-0.98). Conclusions: Cost discussions were infrequently documented in the medical records of patients who were diagnosed with advanced NSCLC and melanoma, which may hinder identifying patient needs and tracking outcomes of associated referrals. Efforts to increase cost-of-care discussions and relevant referrals, as well as their documentation, are warranted.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CML showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CML showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CRC showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CRC showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary materials and methods outline SAS code used to fit flexible parametric survival model. Document includes a simple example along with a link to the Github repository containing full macro code and worked examples.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary materials and methods outline SAS code used to fit flexible parametric survival model. Document includes a simple example along with a link to the Github repository containing full macro code and worked examples.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing model fit criteria for final model for each cancer site.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing model fit criteria for final model for each cancer site.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for DLBCL showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for DLBCL showing treatments that received FDA approval between 1975 and 2018.